此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

化疗引起的非转移性乳腺癌女性头发变化和脱发、皮肤老化和指甲变化的研究

2026年11月10日 更新者:Memorial Sloan Kettering Cancer Center

化疗引起的非转移性乳腺癌女性头发变化和脱发、皮肤老化和指甲变化的前瞻性纵向研究

The purpose of this study is to see how many patients develop hair, skin and nail changes due to cancer treatments. The investigators would like to study the clinical factors, genetic markers, and impact on patients' health-related quality of life to learn more about who is at greater risk. We trust that the study will improve our understanding of how cancer patients feel about their skin, hair, and nail conditions. This information will help us determine the burden on breast cancer patients and survivors. It will also help us learn how to prevent these conditions and it may improve the way we treat them and counsel patients.

研究概览

研究类型

观察性的

注册 (估计的)

546

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • New York
      • New York、New York、美国、10021
        • Memorial Sloan Kettering Cancer Center

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

是的

有资格学习的性别

女性

取样方法

非概率样本

研究人群

MSKCC clinics

描述

Inclusion Criteria:

  • Women newly diagnosed with non-metastatic breast cancer (stage 0-III, any receptor type) at the time of starting chemotherapy (dd-AC-T, CMF, Newer Combination Regimens) or endocrine therapy (tamoxifen, anastrozole, letrozole, exemestane)
  • Women ≥ 18 years at the time of enrollment into the study
  • Able to communicate in English and participate in the informed consent process
  • Able to comply with the follow-up visits, assessments, answering questionnaires

Exclusion Criteria:

  • Metastatic breast cancer
  • Follow-up care/visits not scheduled at MSKCC
  • Any current alopecia especially due to an active scalp and/or hair disorder (e.g. alopecia areata), or a pre-existing condition with sequelae (e.g. scarring alopecia)
  • Currently active or uncontrolled medical condition [e.g. thyroid disorder, auto-immune connective tissue disease (e.g. SLE), BMT complications (GVHD)] or medication intake (e.g. HRT), affecting scalp hair
  • Prior systemic treatment for any malignancy
  • Active secondary cancer requiring cytotoxic chemotherapy
  • Planned (or a history of) radiation therapy to the head
  • Vulnerable populations [e.g. decisionally impaired (cognitive, psychiatric), terminally ill, prisoners], or patients who, in the opinion of the investigator have a condition that precludes their ability to provide an informed consent
  • Men

Volunteer Inclusion Criteria:

  • Post menopausal women, with menopausal status defined as (per self report):
  • Bilateral salpingo-oophorectomy independent of age
  • If natural menopause, age ≥ 50 with cessation of menses for at least 12 months
  • Or premenopausal women with premenopausal status defined as <53 years of age with no cessation of menses
  • Able to communicate in English and participate in the informed consent process
  • Able to comply with the baseline assessments and answering questionnaires
  • Women >/= 18 years at the time of enrollment into the study

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 观测模型:CASE_CONTROL
  • 时间观点:RETROSPECTIVE

队列和干预

团体/队列
干预/治疗
Patients having CYTOTOXIC CHEMOTHERAPY

Participants will undergo study related assessments and the appropriate HRQoL questionnaires will be administered. Baseline and follow-up clinical assessments will be performed, preferably when the patient presents to the clinic for (clinically indicated) standard-of-care visits. Initially, these visits will be coinciding with the appropriate chemotherapy dosing cycles (as applicable to select study cohorts), and subsequently they will be performed during the standard-of-care follow-up visits.

(only once, preferably at baseline)

Patients having ENDOCRINE THERAPY

Participants will undergo study related assessments and Medical and Personal History Questionnaire data collection forms and the appropriate HRQoL questionnaires, will be administered. Baseline and follow-up clinical assessments will be performed, preferably when the patient presents to the clinic for standard-of-care visits. Initially, these visits will be coinciding with the appropriate therapy and subsequently they will be performed during the standard-of-care follow-up visits.

(only once, preferably at baseline)

COMPARATOR (menopausal women)

Menopausal women will include unrelated visitors accompanying breast cancer patients (e.g. friends) attending the breast medicine or dermatology clinics, or female employees of MSKCC. There will be no follow-up visits (after baseline) for participants in the comparator cohort.

(only once, preferably at baseline)

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Incidence of persistent alopecia
大体时间:1 year

as assessed clinically and by phototrichogram assessments, among women exposed to cytotoxic chemotherapy

1 year
Incidence of alopecia
大体时间:1 year

as assessed clinically and by phototrichogram assessments, among women exposed to endocrine therapies

1 year

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Alina Markova, MD、Memorial Sloan Kettering Cancer Center

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2015年8月19日

初级完成 (估计的)

2027年8月1日

研究完成 (估计的)

2027年8月1日

研究注册日期

首次提交

2015年8月19日

首先提交符合 QC 标准的

2015年8月19日

首次发布 (估计的)

2015年8月20日

研究记录更新

最后更新发布 (实际的)

2026年11月13日

上次提交的符合 QC 标准的更新

2026年11月10日

最后验证

2026年11月1日

更多信息

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅